| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Halozyme Therapeutics missed estimated earnings by 1.2%, reporting an EPS of $0.82 versus an estimate of $0.83.
Revenue was up $48.54 million from the same period last year.
Last quarter the company beat on EPS by $0.02 which was followed by a 10.04% increase in the share price the next day.
Here's a look at Halozyme Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.73 | 0.63 | 0.48 | 0.47 |
| EPS Actual | 0.75 | 0.74 | 0.47 | 0.48 |
| Revenue Estimate | 222.63M | 199.32M | 175.51M | 192.05M |
| Revenue Actual | 216.03M | 221.04M | 162.14M | 181.50M |
To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: HALO
